CRISPR/Cas9-mediated activation of CDH1 suppresses metastasis of breast cancer in rats

Background: Cancer is a life-threatening disease that affects approximately 18 million individuals worldwide. Breast cancer is the most common female neoplasm globally with more than 276,480 new cases of invasive breast cancer expected to be diagnosed in women in the U.S. alone in 2020. Genetic and epigenetic factors play role in the carcinogenesis and progression of this disease. In this study, MCF-7 adenocarcinoma cells were transfected with CRISPR/Cas9 plasmid to either knock out CDK11 or to activate CDH1. Treated cells were allografted into the mammary glands of female rats (150-190 g, 6-8 weeks) to evaluate the capability of these cells to control cancer progression and metastasis. Results: qPCR data revealed a significant downregulation of CDK11 and upregulation of CDH1. Cell cycle analysis and apoptosis assays indicated the knockout of CDK11 and simultaneous activation of CDH1 resulted in cell cycle arrest at G2/M phase and accumulation of cells at G2. Meanwhile, the percentage of cells that underwent late apoptosis increased in both genome editing hits. Histopathological sectioning data indicated that untransfected MCF-7 cells were capable of developing tumors in the mammary gland and initiation g angiogenesis. Transfected cells significantly restricted cancer cell infiltration/invasion by minimally localizing tumors and inhibiting angiogenesis. Conclusions: Although further investigation is needed, the present data indicate the potentiality of using CRISPR/Cas9-based therapy as a promising approach to treat breast cancer. Impact: these data indicate targeting cancer-related genes via any genome editing tool might represent a novel approach to combat cancer. (C) 2021 Pontificia Universidad Catolica de Valparaiso. Production and hosting by Elsevier B.V.

Automated summary

This study demonstrated that knockout of CDK11 and activation of CDH1 using CRISPR/Cas9 technology can effectively inhibit cell cycle progression and reduce tumor cell infiltration. These findings suggest that CRISPR/Cas9 may be a promising approach for treating breast cancer.